NCT04061421View on ClinicalTrials.gov

Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

December 10, 2021

Primary Completion Date

August 31, 2024

Study Completion Date

August 31, 2025

Conditions
MDS/MPN
Interventions
DRUG

ASTX727

Taken by mouth daily during days 1-5 of every 28-day cycle.

DRUG

Itacitinib

Taken by mouth daily during each 28-day cycle

Trial Locations (1)

37232

RECRUITING

Vanderbilt-Ingram Cancer Center, Nashville

Sponsors

Lead Sponsor

Michael Savona
All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

collaborator

Theradex

INDUSTRY

collaborator

Astex Pharmaceuticals, Inc.

INDUSTRY

lead

Michael Savona

OTHER